Orthofix Medical Inc. (NASDAQ:OFIX) Q3 2025 Financial Performance Overview

Core Insights - Orthofix Medical Inc. reported a Q3 2025 EPS of -$0.57, missing the estimated EPS of $0.12, but exceeded revenue expectations with approximately $205.6 million [1][5] - The company has adjusted its full-year 2025 net sales guidance and increased the lower end of its adjusted EBITDA guidance, indicating a strategic approach to future growth [2][5] Financial Performance - The negative price-to-earnings (P/E) ratio of -4.88 indicates negative earnings, while the price-to-sales ratio of 0.75 suggests the stock is valued at 75 cents for every dollar of sales [3][5] - The enterprise value to sales ratio is 0.92, reflecting the company's valuation in relation to its revenue [3] - The enterprise value to operating cash flow ratio is 25.92, showing how many times the operating cash flow can cover the enterprise value [4] - An earnings yield of approximately -20.50% emphasizes the negative earnings [4] - The debt-to-equity ratio of about 0.45 indicates a moderate level of debt compared to equity [4][5] - A current ratio of 2.67 suggests a robust ability to cover short-term liabilities with short-term assets [4][5] Strategic Considerations - The company is navigating challenges, including the discontinuation of its M6™ product lines, while its revenue performance and financial adjustments signal a strategic approach to future growth [4]